Клиническое значение реактивного клеточного микроокружения при фолликулярных лимфомах
Диссертация
Разумеется, статья породила целый ряд вопросов. Как соотносится прогностическая значимость IR1 и IR2 с цитологическим типом фолликулярных лимфом и наличием зон диффузного роста (Kobayashi К. at al., 2005). Играет ли роль инфильтрация иммунными клетками собственно опухолевых фолликулов (Naresh K.N., 2005). Возможно и то, что рост фолликулярной лимфомы подавляет иммунную систему… Читать ещё >
Содержание
- Список сокращений
- Глава I. Обзор литературы
- 1. 1. Фолликулярная лимфома. Общие положения
- 1. 2. Роль микроокружения при солидных опухолях и фолликулярной лимфоме
- 1. 2. 1. Т-регуляторные клетки
- 1. 2. 2. Т-регуляторные клетки в нормальной лимфоидной ткани
- 1. 2. 3. Т-регуляторные клетки при фолликулярной лимфоме
- 1. 2. 4. Тумор-ассоциированные макрофаги при фолликулярной лимфоме
- 1. 2. 5. PD1-позитивные лимфоциты в ткани фолликулярных лимфом
- 111. 1. Морфологическая характеристика фолликулярной лимфомы
- 111. 2. Иммунологическая характеристика фолликулярной лимфомы
- III. 2.1. Взаимосвязь между иммунофенотипическими характеристиками опухоли и субпопуляциями клеток микроокружения при фолликулярной лимфоме
- 111. 3. Взаимосвязь морфологических и иммунологических характеристик фолликулярной лимфомы
- 111. 3. 1. Связь цитологического типа по клеточному составу с иммунологическими характеристиками фолликулярной лимфомы
- 111. 3. 2. Взаимосвязь цитологического типа фолликулярной лимфомы с клетками неопухолевого микроокружения
- 111. 3. 3. Связь иммунофенотипа фолликулярной лимфомы с характером роста опухолевых клеток
- 111. 3. 4. Взаимосвязь характера роста фолликулярной лимфомы с клетками неопухолевого микроокружения
- 111. 3. Взаимосвязь морфологических и иммунологических характеристик фолликулярной лимфомы
- IV. 1. Влияние клинических факторов на прогноз фолликулярной лимфомы
- IV. 2. Влияние морфологических факторов на прогноз фолликулярной лимфомы
Список литературы
- Давыдов М.И., Аксель Е. М. // Статистика злокачественныхновообразований в России и странах СНГ в 2009г. // Москва, Вестник РОНЦ им. Н. Н. Блохина РАМН, 2011, т.22, № 3 (прил.1).
- Ковригина A.M., Пробатова Н. А. // Дифференциальная диагностиканеходжкинских В-клеточных лимфом. // Онкогематология, 2007, 2, 4−9.
- Ковригина A.M. // Морфологическая характеристика реактивных измененийлимфоузлов. // Клиническая онкогематология, 2009, т2, 4, 297−305.
- Поддубная И.В. // Неходжкинские лимфомы. В книге «Клиническаяонкология». // Под редакцией Давыдова М. И., Москва, 2004, 615−630.
- Поддубная И.В. // Неходжкинские лимфомы. В книге «Клиническаяонкогематология». // Под редакцией Волковой М. А., Медицина, 2001, 336 375.
- Пробатова Н.Н., Ковригина A.M. // Морфология неходжкинских лимфом илимфомы Ходжкина. В книге «клиническая онкогематология». // Под редакцией Волковой М. А., Медицина, 2007, 322−323.
- Руководство по гематологии в 3 т. Т.1. Под ред. А. И. Воробьева. М.:1. Ньюдиамед, 2002, 280с.
- Тумян Г. С. // Поддерживающая терапия ритуксимабом при В-клеточныхнеходжкинских лимфомах. // Клиническая онкогематология, 2009, т2, 1, 147−151.
- Тумян Г. С. // Диффузная В-крупноклеточная лимфома. Фолликулярнаялимфома. Современные принципы лечения. // Онкогематология (специальный выпуск), 2011, 27−33.
- Ahmadzadeh</span> М., Rosenberg S.A. // IL-2 administration increases
- CD4+CD25hiFoxp3+ regulatory T cells in cancer patients. // Blood, 2006, 107, 2409−2414.
- Ai W., Hou J., Zeiser R. et al. // Follicular lymphoma derived В cells aresufficient to convert CD4 T cells into CD4-CD25- FOXP3 regulatory T cells viacell-cell contact without stimulation of T cell receptor. // Ann. Oncol., 2008, 19, ivl01-ivl02.
- Allan SE., Passerini L., Bacchetta R. et al. // The role of 2 FOXP3 isoforms in thegeneration of human CD4+ Tregs. // J. Clin. Invest., 2005, 115, 3276−3284.
- Almeida AR., Legrand N., Papiernik M. et al. 2002. // Homeostasis of peripheral
- CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. // J. Immunol., 169, 4850−4860.
- Alvaro T., Lejeune M., Salvado MT. et al. // Outcome in Hodgkin’s lymphomacan be predicted from the presence of accompanying cytotoxic and regulatory T cells. // Clin. Cancer Res., 2005, 11, 1467−1473.
- Alvaro T., Lejeune M., Salvado M.T. et al. // Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. // J. Clin. Oncol., 2006, 24, 5350−5357.
- Anderson J.R., Armitage J.O., Weisenburger D.D. // Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. // Ann. Oncol., 1998, 9,717−720.
- Anderson J.R., Vose J.M., Bierman P.J. et al. // Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group. //J. Clin. Oncol., 1993, 11, 218−224.
- Anderson T., Bender R.A., Fisher R.I. et al. // Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term follow up. // Cancer Treat Rep., 1977,61, 1057−1066.
- Anon. // A clinical evaluation of the International Lymphoma Study Groupclassification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Progect. // Blood, 1997, 89, 3909−3918.
- Anon. // A predictive model for aggressive non-Hodgkin's lymphoma. The1. ternational Non-Hodgkin's Lymphoma Prognostic Factors Project. // N. Engl. J. Med, 1993, 329, 987−994.
- Anon. // National Cancer Institute sponsored study of classifications of non
- Hodgkin’s lymphomas: summary and description of a working formulation for136clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. //Cancer, 1982, 49, 2112−2135.
- Asseman C., Mauze S., Leach M.W. et al. // An essential role for interleukin 10in the function of regulatory T cells that inhibit intestinal inflammation. // J. Exp. Med, 1999, 190, 995−1004.
- Au W. Y, Horsman D.E., Gascoyne R.D. et al. // The spectrum of lymphomawith 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases. // Leuk Lymphoma, 2004, 45, 519−528.
- Awwad M, North R.J. // Cyclophosphamide-induced immunologically mediatedregression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. // Cancer Res, 1989, 49, 16 491 654.
- Azuma T, Takahashi T, Kunisato A, et al. // Human CD4+ CD25+ regulatory Tcells suppress NKT cell functions. // Cancer Res, 2003, 63, 4516−4520.
- Baecher-Allan C, Brown J. A, Freeman G.J. et al. // CD4+CD25+ highregulatory cells in human peripheral blood. // J. Immunol, 2001, 167, 12 451 253.
- Bartlett N. L, Rizeq M, Dorfman R.F. et al. // Follicular large-cell lymphoma: intermediate or low grade? // J. Clin. Oncol, 1994, 12, 1349−1357.
- Berg D.J. et al. // Enterocolitis and colon cancer in interleukin-10-deficient miceare associated with aberrant cytokine production and CD4+ THl-like responses. //J. Clin. Invest, 1996, 98, 1010−1020.
- BetzA.G, Neuberger M.S., Milstein C. // Discriminating intrinsic and antigen-selected mutational hotspots in immunoglobulin V genes. // Immunol. Today, 1993, 14, 405−411.
- Beyer M.*, Kochanek M., Giese T. et al. // In vivo peripheral expansion of naive
- CD4+CD25high FOXP3+ regulatory T cells in patients with multiple myeloma. // Blood, 2006, 107, 3940−3949.
- Beyer M., Kochanek M., Darabi K., et al. // Reduced frequencies and suppressivefunction of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. // Blood, 2005, 106, 20 182 025.
- Beyer M., Schultze J.L. // Regulatoty T cells in cancer. // Blood, 2006, 108, 804 811.
- Bienvenu B., Martin B., Auffray C. et al. // Peripheral CD8+CD25+ Tlymphocytes from MHC class II-deficient mice exhibit regulatory activity. // J. Immunol., 2005, 175(1), 246−253.
- Bingle L., Brown N.J., Lewis C.E. // The role of tumour-associated macrophagesin tumour progression: implications for new anticancer therapies. // J. Pathol. 2002, 196, 254−265.
- Blair P.J. et al. // CD4+CD8+ T cells are the effector cells in diseasepathogenesis in the scurfy (sf) mouse. // J. Immunol., 1994, 153, 3764−3774.
- Blank C., Kuball J., Voelkl S. et al. // Blokade of PD-1 (B7-H1) augments humantumor-specific T cell responses in vitro. // Int. J. Cancer., 2006, Jul 15, 119, 31 727.
- Brody J., Ai W.Z., Czerwinski D. et al. // Clinical and immunologic responses toa novel in situ lymphoma vaccine maneuver: preliminary results of a phase II trial of intra-tumoral CpG 7909. // J. Clin. Oncol., 2008, 26(15 suppl), 3003.
- Brown J.A., Dorfman D.M., Ma F.R. et al. // Blockade of programmed death-1ligands on dendritic cells enhances T cell activation and cytokine production. // J. Immunol., 2003, 170, 1257−66.
- Bruder B. et al. // Neuropilin-1: a surface marker of regulatory T cells. // Eur. J.1.munol, 2004, 34, 623−630.
- Brunkow M.E., Jeffery E.W., Hjerrild K.A. et al. // Disruption of a newforkhead/winged-helix protein, scurfm, results in the fatal lymphoproliferative disorder of the scurfy mouse. // Nat Genet., 2001, 27, 68−73.
- Bystry R.S., Aluvihare V., Welch K.A. et al. // B cells and professional APCsrecruit regulatory T cells via CCL4. // Nat. Immunol., 2001, 2, 1126−1132.
- Carreras J., Lopez-Guillermo A., Fox B.C. et al. // High numbers of tumorinfiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. // Blood, 2006, 108(9), 2957−2964.
- Cattoretti G., Chang C.C., Cechova K. et al. // BCL-6 protein is expressed ingerminal-center B cells. // Blood, 1995, 86, 45−53.
- Cederbom L., Hall H., Ivars F. // CD4+CD25+ regulatory T cells down-regulatecostimulatory molecules on antigen-presenting cells. // Eur. J. Immunol., 2000, 30, 1538−1543.
- Chai J.G., Xue S.A., Coe D. et al. // Regulatory T cells, derived from naive
- CD4+CD25-T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance. // Transplantation, 2005, 79, 1310−6.
- Chakraborty N.G., Chattopadhyay S., Mehrotra S. et al. // Regulatory T-cellresponse and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. // Hum. Immunol., 2004, 65, 794−802.
- Chakraborty N.G., Twardzik D.R., Sivanandham M. et al. // Autologousmelanoma-induced activation of regulatory T cells that suppress cytotoxic response. // J. Immunol., 1990, 145, 2359−2364.
- Chen W. // Dendritic cells and (CD4+)CD25+ T regulatory cells: crosstalkbetween two professionals in immunity versus tolerance. // Front/ Biosci., 2006, 11, 1360−1370.
- Chen Y., Kuchroo V.K., Inobe J. et al. // Regulatory T cell clones induced by oraltolerance: suppression of autoimmune encephalomyelitis. // Science., 1994, 265, 1237−1240.
- Collins A.V. et al. // The interaction properties of costimulatory moleculesrevisited. // Immunity., 2002, 17, 201−210.
- Cong P., Raffeld M., Teruya-Feldstein J. et al. // In situ localization of follicularlymphoma: description and analysis by laser capture microdissection. // Blood, 2002, 99, 3376−3382.
- Curiel T.J.*, Coukos G., Zou L. et al. // Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. //Nat. Med., 2004, 10(9), 942−949.
- Curiel T.J., Cheng P., Mottram P. et al. // Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. // Cancer Res., 2004, 64, 55 355 538.
- Dannull J., Su Z, Rizzieri D. et al. // Enhancement of vaccine-mediatedantitumor immunity in cancer patients after depletion of regulatory T cells. // J. Clin. Invest, 2005, 115, 3623−3633.
- Dave S.S., Wright G., Tan B. et al. // Prediction of survival in follicularlymphoma based on molecular features of tumor-infiltrating immune cells. // N. Engl. J. Med., 2004, 351, 2159−2169.
- De Groot A.S., Moise L., McMurry J.A. et al. // Activation of natural regulatory
- De La Rosa, Rutz S., Dorninger H. et al. // Interleukin-2 is essential for
- CD4+CD25+ regulatory T cell function. // Eur. J. Immunol., 2004, 34, 24 802 488.
- Dogan A., Du M.Q., Aiello A. et al. // Follicular lymphomas contain a clonallylinked but phenotypically distinct neoplastic B-cell population in the interfollicular zone. //Blood, 1998, 91, 4708−4714.
- Dorfman D.M., Brown J.A., Shahsafaei A. et al. // Programmed death-1 (PD-1) isa marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. // Am. J. Surg. Pathol., 2006, 30, 802−10.
- Dudley M.E., Wunderlich J.R., Robbins P.F. et al. // Cancer regression andautoimmunity in patients after clonal repopulation with antitumor lymphocytes. // Science, 2002, 298, 850−854.
- Dunn G.P., Old L.J., Schreiber R.D. // The immunobiology of cancerimmunosurveillance and immunoediting. // Immunity, 2004, 21(2), 137−148.
- Ercolini A.M., Ladle B.H., Manning E.A. et al. // Recruitment of latent pools ofhigh-avidity CD8(+)T cells to the antitumor immune response. // J. Exp. Med., 2005, 201, 1591−1602.
- Eshoa C., Perkins S., Kampalath B., et al. // Decreased CD10 expression in Grade III and in interfollicular infiltrates of follicular lymphomas. // Am. J. Clin. Pathol., 2001, 115, 862−867.
- Fallarino F. et al. // Modulation of tryptophan catabolism by regulatory T cells. //
- Nat. Immunol., 2003, 4, 1206−1212.
- Farinha P, Al-Tourah A, Gill K. et al. //The architectural pattern of FOXP3positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. // Blood, 2010, 115, 289−295.
- Farinha P, Masoudi H, Skinnider B.F. et al. // Analysis of multiple biomarkersshows that lymphomaassociated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). // Blood, 2005, 106(6), 21 692 174.
- Fattorossi A, Battaglia A, Ferrandina G. et al. // Neoadjuvant therapy changesthe lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma.//Cancer, 2004, 100, 1418−1428.
- Fehervari Z, Sakaguchi S. // CD4+ Tregs and immune control. // J. Clin. Invest, 2004, 114, 1209−1217.
- Fife B. T, Bluestone J.A. // Control of peripheral T-cell tolerance andautoimmunity via the CTLA-4 and PD-1 pathways. // Immunol. Rev, 2008, 224, 166−82.
- Finn L. S, Viswanatha D. S, Belasco J.B. et al. // Primary follicular lymphoma ofthe testis in childhood. // Cancer, 1999, 85, 1626−1635.
- Fleishman E. W, Prigogina E. L, Ilynskaya G.W. et al. // Chromosomal characteristics of malignant lymphoma. // Hum. Genet, 1989, 82, 4, 343−348.
- Fontenot J. D, Gavin M. A, Rudensky A.Y. // Foxp3 programs the developmentand function of CD4+CD25+ regulatory T cells. // Nat. Immunol, 2003, 4, 330 336.
- Fontenot J. D, Rasmussen J. P, Williams L.M. et al. // Regulatory T cell lineagespecification by the forkhead transcription factor foxp3. // Immunity, 2005, 22, 329−41.
- Gajewski T.F. // Lymphoma-infiltrating immune cells. To the editor. // N. Engl. J. Med, 2005, 352- 7, 725.
- Gallagher C. J, Gregory W. M, Jones A.E. et al. // Follicular lymphoma: prognostic factors for response and survival. // J. Clin. Oncol, 1986, 4, 14 701 480.
- Ganti A. K, Weisenburger D. D, Smith L.M. et al. // Patients with grade 3follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. // Ann. Oncol, 2006, 17, 920−927.
- Gavin M. A, Clarke S. R, Negrou E. et al. // Homeostasis and anergy of
- CD4+CD25+ suppressor T cells in vivo. //Nat. Immunol, 2002, 3, 33−41.
- Gershon R. K, Kondo K. // Infectious immunological tolerance. // Immunology, 1971,21,903−914.
- Ghiringhelli F, Larmonier N, Schmitt E. et al. // CD4+CD25+ regulatory T cellssuppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. // Eur. J. Immunol, 2004, 34, 336−344.
- Glas A.M., Kersten M. J, Delahaye L.J. et al. // Gene expression profiling infollicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. // Blood, 2005, 105, 301−7.
- Glas A.M., Knoops L, Delahaye L. et al. // Gene-expression andimmunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. // J. Clin. Oncol, 2007, 25, 390−398.
- Glick J. H, Barnes J. M, Ezdilni E.Z. et al. // Nodular mixed lymphoma: results ofa randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. // Blood, 1981, 58, 920−925.
- Glick J.H., McFadden E., Costello W. et al. 11 Nodular histiocytic lymphoma: factors influencing prognosis and implications for aggressive chemotherapy. // Cancer, 1982, 49, 840−845.
- Golgher D., Jones E., Powrie F. et al. // Depletion of CD25+ regulatory cellsuncovers immune responses to shared murine tumor rejection antigens. // Eur. J. Immunol, 2002, 32, 3267−3275.
- Goodlad J.R., Batstone P.J., Hamilton B. et al. // Follicular lymphoma withmarginal zone differentiation: cytogenetic findings in support of a high-risk variant of follicular lymphoma. // Histopathology, 2003, 42, 292−298.
- Gray C.P., Arosio P., Hersey P. // Association of increased levels of heavy-chainferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma. // Clin. Cancer Res., 2003, 9, 2551−2559.
- Gray C.P., Arosio P., Hersey P. // Heavy chain ferritin activates regulatory Tcells by induction of changes in dendritic cells. // Blood, 2002, 99, 3326−3334.
- Greenberg P.D., Cheever M.A., Fefer A. // Eradication of disseminated murineleukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-l+2-lymphocytes. // J. Exp. Med., 1981, 154, 952−963.
- Greenfield E.A. et al. // B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. // J. Immunol., 1997, 158, 2025−2034.
- Grohmann U. et al. // CTLA-4-Ig regulates tryptophan catabolism in vivo. // Nat. Immunol., 2002, 3, 1097−1101.
- Groux H. // Type 1 T-regulatory cells: their role in the control of immune responses. // Transplantation, 2003, 75(Suppl. 9), 8S-12S.
- Groux H. et al. // A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. //Nature, 1997, 389, 737−742.
- Hammerling G. L, Klar D, Pulm W. et.al. // The influence of major histocompatibility complex class I antigens on tumor growth and metastasis. // Bioch. et Bioph. Acta, 1987, V.907, N3, P.245−258.
- Hans C. P, Weisenburger D. D, Vose J.M. et al. // A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. // Blood, 2003, 101, 2363−2367.
- Hara M, Kingsley C. I, Niimi M. et al. //11−10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. // J. Immunol, 2001, 166, 37 893 796.
- Harjunpaa A, Taskinen M, Nykter M. et al. // Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. // Br. J. Haematol, 2006, 135, 33−42.
- Harris N. L, Swerdlow S. H, Jaffe E.S. et al. // Follicular lymphoma. In: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues (Swerdlow SH et al. Eds). // IARC: Lyon 2008, P. 220 226.
- Hasselblom S, Sigurdadottir M, Hansson U. et al. // The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. // Br. J. Haematol, 2007, 137, 36 473.
- Hilchey S. P, De A, Rimsza L.M. et al. // Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25+ and CD4+CD25+ T cells. //J. Immunol, 2007, 178(7), 4051−4061.
- Hiura T, Kagamu H, Miura S. et al. // Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. //J. Immunol, 2005, 175, 5058−5066.
- Hoglung M., Sehn L., Connors J.M. et al. // Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. // Genes Chromosomes Cancer, 2004, 39, 195−204.
- Hori S., Nomura T., Sakaguchi S. // Control of regulatory T cell development by the transcription factor Foxp3. // Science, 2003, 299(5609), 1057−1061.
- HornaP., Cuenca A., Cheng F. et al. // In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. // Blood, 2006, 107, 2871−2878.
- Horsman D.E., Gascoyne R.D., Coupland R.W. et al. // Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t (14−18) in follicular lymphoma. // Am. J. Clin. Pathol., 1995, 103, 472−478.
- Houot R., Levy R. // T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. // Blood, 2009, 113(15), 3546−3552.
- Huang C.T. et al. // Role of LAG-3 in regulatory T cells. // Immunity, 2004, 21(4), 503−513.
- Husson H., Carideo E.G., Neuberg B. et al. // Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. // Blood, 2002, 99, 282−9.
- Ichihara F., Kono K., Takahashi A. et al. // Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. // Clin. Cancer. Res., 2003, 9, 4404−4408.
- Iwai Y., Terawaki S., Honjo T. // PD-1 blokade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. // Int. Immunol., 2005, 17, 133−44.
- Jaffe E.S., Harris N.L., Stein H. et al. // Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. // IARCPress: Lyon, 2001.
- Janssens W, Carlier V., Wu B. et al. // CD4+CD25+ T cells lyse antigen-presenting B cells by Fas-Fas ligand interaction in an epitope-specific manner. // J. Immunol, 2003, 171, 4604−4612.
- Javia L.R., Rosenberg S.A. // CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. // J. Immunother. 2003, 26, 85−93.
- Jones S.E., Fuks Z., Bull M. et al. // Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. // Cancer, 1973, 31, 806−823.
- Jonuleit H., Schmitt E., Steinbrink K. et al. // Dendritic cells as a tool to induce anergic and regulatory T cells. // Trends Immunol., 2001, 22, 394−400.
- Jordan M.S. et al. // Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. //Nat. Immunol., 2001, 2, 301−306.
- Kantarjian H.M., McLaughlin P., Fuller L.M. et al. // Follicular large cell lymphoma: analysis and prognostic factors in 62 patients. // J. Clin. Oncol., 1984, 2, 811−819.
- Karube K., Guo Y., Suzumiya J. et al. // CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. // Blood, 2007, 109, 3076−3079.
- Katzenberger T., Ott G., Klein T. et al. // Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. // Am. O. Pathol., 2004, 165, 481−490.
- Keir M.E., Butte M.J., Freeman G.J. et al. // PD-1 and its ligands in tolerance and immunity. // Annu. Rev. Immunol., 2008, 26, 677−704.
- Kemper C. et al. // Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. //Nature, 2003, 421, 388−392.
- Khattri R., Cox T., Yasayko S.A. et al. // An essential role for Scurfin in CD4+CD25+ T regulatory cells. // Nat. Immunol., 2003, 4, 337−342.
- Kobayashi K., Murashige N., Kishi Y. // Lymphoma-infiltrating immune cells. To the editor. // N. Engl. J. Med., 2005, 352, 7, 724.
- Kono K, Kawaida H, Takahashi A. et al. // CD4(+) CD25(high) regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. // Cancer Immunol Immunother, 2006, 55, 1064−1071.
- Koster A, Tromp H. A, Raemaekers J.M. et al. // The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma. // Haematologica, 2007, 92, 184−190.
- Kumanogoh A, et al. // Increased T cell autoreactivity in the absence of CD40-CD40 ligand interactions: a role of CD40 in regulatory T cell development. // J. Immunol, 2001, 166, 353−360.
- Lai R, Weiss L. M, Chang K.L. et al. // Frequency of CD43 expression in non-Hodgkin's lymphoma. A survey of 742 cases and further characterization of rare CD43+ follicular lymphomas. // Am. J. Clin. Pathol, 1999, 111: 488−494.
- Lee A.M., Clear A. J, Calaminici M. et al. // Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. // J. Clin. Oncol, 2006, 24, 50 525 059.
- Lehmann J. et al. // Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. // Proc. Natl. Acad. Sci. USA, 2002, 99, 13 031−13 036.
- Lim H. W, Hillsamer P, Banham A.H. et al. // Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. // J. Immunol, 2005, 175, 41 804 183.
- Lim H. W, Hillsamer P, Kim C.H. // Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. // J. Clin. Invest, 2004, 114, 1640−1649.
- Liu J. Y, Zhang X. S, Ding Y. et al. // The changes of CD4+CD25+/CD4+ proportion in spleen of tumor-bearing BALB/c mice. // J. Transl. Med, 2005, 3, 5.
- Longo D. L, Young R. C, Hubbard S.M. et al. // Prolonged initial remission in patients with nodular mixed lymphoma. // Ann. Intern. Med, 1984, 100, 651 656.
- Lorbach R. B, Shay-Seymore D, Moore J. et al. // Clinicopathologic analysis of follicular lymphoma occurring in children. // Blood, 2002, 99, 1959−1964.
- Lutsiak M. E, Semnani R. T, De Pascalis R. et al. // Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. //Blood, 2005, 105, 2862−2868.
- Lyon M. F, Peters J, Glenister P.H. et al. // Yhe scurfy mouse mutant previously unrecognized haematological abnormalities and resembles Wiskott-Aldrich syndrome. // Proc. Natl. Acad. Sci. USA, 1990, 87, 2433−2437.
- Malek T. R, Bayer A.L. // Tolerance, not immunity, crucially depends on IL-2. // Nat. Rev. Immunol, 2004, 4, 665−674.
- Malek T. R, Yu A, Vincek V. et al. // CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundand function of IL-2. // Immunity, 2002, 17, 167−178.
- Maloy K.J. et al. // CD4+CD25+ T ® cells suppress innate immune pathology through cytokinedependent mechanisms. // J. Exp. Med, 2003, 197, 111−119.
- Mann R. B, Berard C.W. // Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. // Hematol. Oncol, 1983, 1, 187−192.
- Mantovani A, Sozzani S, Locati M. et al. // Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. // Trends Immunol, 2002, 23, 549−555.
- Mariani S, Coscia M, Even J. et al. // Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. // Br. J. Haematol, 2001, 113, 1051−1059.
- Marinova E, Han S, Zheng B. // Germinal center helper T cells are dual functional regulatory cells with suppressive activity to conventional CD4+ T cells. // J. Immunol, 2007, 178, 5010−7.
- Marshall N. A, Christie L. E, Munro L.R. et al. // Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. // Blood, 2004, 103, 1755−1762.
- Martin A.R., Weisenburger D.D., Chan W.C. et al. // Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. // Blood, 1995, 85, 3671−3678.
- McHugh R.S., Whitters M.J., Piccirillo C.A. et al. // CD4+ CD25+ immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. // Immunity, 2002, 16, 311−323.
- McLaughlin P., Fuller L.M., Velasques W.S. et al. // Stage III follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. // J. Clin. Oncol., 1987, 5, 867−874.
- Mills C.D., Kincaid K., Alt J.M. et al. // M-l/M-2 macrophages and the Thl/Th2 paradigm. // J. Immunol., 2000, 164, 6166−6173.
- Mills K.H., McGuirk P. // Antigen-specific regulatory T cells—their induction and role in infection. // Semin. Immunol. 2004, 16, 107−117.
- Mittal S., Marshall N.A., Duncan L. et al. // Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. // Blood, 2008, 111(11), 5359−5370.
- Morgan M.E., van Bilsen J.H., Bakker A.M. et al. // Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. // Hum. Immunol., 2005, 66, 13−20.
- Motta M., Rassenti L., Shelvin BJ. et al. // Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. // Leukemia, 2005, 19, 1788−1793.
- Munn D.H., Sharma M.D., Mellor A.L. // Ligation of B7−1/B7−2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. // J. Immunol., 2004, 172, 4100−4110.
- Murakami M, Sakamoto A, Bender O. et al. // CD25+CD4+ T cells contribute to the control of memory CD8+ T cells. // Proc. Natl. Acad. Sci. USA, 2002, 99, 8832−8837.
- Nakamura K, Kitani A, Strober W. // Cell contact-dependent immunosupression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor beta. // J. Exp. Med, 2001, 194, 629 644.
- Naresh K.N. // Lymphoma-infiltrating immune cells. To the editor. // N. Engl. J. Med, 2005, 352, 7, 724.
- Nathwani B. N, Anderson J. R, Armitage J.O. et al. // Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin's Lymphoma Classification Progect. // Hum. Pathol, 1999, 30, 263−268.
- Nathwani B. N, Metter G. E, Miller T.P. et al. // What should be the morphologic criteria for the subdivision of follicular lymphomas? // Blood, 1986, 68, 837−845.
- Nishikawa H, Jager E, Ritter G. et al. // CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. //Blood, 2005, 106(3), 1008−1011.
- Nishikawa H, Kato T, Tanida K. et al. // CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. // Proc. Natl. Acad. Sci. USA, 2003, 100, 10 902−10 906.
- Ohigashi Y, Sho M, YamadaY. et al. // Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. // Clin. Cancer Res, 2005, 11, 2947−53.
- Oida T. // CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45high-induced colitis by a TGF-beta-dependent mechanism. // J. Immunol, 2003, 170, 2516−2522.
- Papernik M, de Moraes M. L, Pontoux C. et al. // Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. // Int. Immunol, 1998, 10, 371−378.
- Piccirillo C. A, Shevach E.M. // Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. // J. Immunol, 2001, 167, 1137−1140.
- Pinto A, Hutchison R. E, Grant L.H. et al. // Follicular lymphomas in pediatric patients. // Mod. Pathol, 1990, 3, 308−313.
- Pittaluga S, Ayoubi T. A, Wlodarska I. et al. // BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas. // J. Pathol, 1996, 179, 145−150.
- Plumas J., Jacob M.C., ChaperotL. et al. // Tumor B cells frm non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-l)-mediated apoptosis. // Blood, 1998,91,2875−2885.
- Pollard J.W. // Tumour-educated macrophages promote tumour progression and metastasis. //Nat. Rev. Cancer., 2004, 4, 71−78.
- Powrie F., Leach M.W., Mauze S. et al. // Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scidmice. //Int. Immunol., 1993, 5, 1461−1471.
- Prabhala R.H., Neri P., Bae J.E. et al. // Dysfunctional T regulatory cells in multiple myeloma. // Blood, 2006, 107, 301−4.
- Prabhu Das M.R., Zamvil S.S., Borriello Fet al. // Reciprocal expression of co-stimulatory molecules, B7−1 and B7−2, on murine T cells following activation. // Eur. J. Immunol., 1995, 25, 207−211.
- Prasad S.J., Farrand K.J., Matthews S.A. et al. // Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+ CD25+ regulatory T cells. // J. Immunol., 2005, 174, 90−98.
- Rappaport H., Winter W., Hicks Y. II Follicular lymphoma. A re-evalution of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. // Cancer, 1956, 9, 792−821.
- Read S., Malmstrom V., Powrie F. et al. // Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. // J. Exp. Med., 2000, 192, 295−302.
- Riley J.L. // PD-1 signaling in primary T cells. // Immunol. Rev., 2009, 229, 114−25.
- Rodrigues J., McLaughlin P., Hagemeister F.B. et al. // Follicular large cell lymphoma: an aggressive lymphoma that often presents with favourable prognostic features. // Blood, 1999, 93, 2202−2207.
- Romagnani C, Delia Chiesa M, Kohler S. et al. // Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. // Eur. J. Immunol, 2005, 35, 2452−2458.
- Roncador G, Garcia J. F, Maestre L. et al. // FOXP3, a selective marker for a subset of adult T-cell leukaemia/lymphoma. // Leukemia, 2005, 19(12), 22 472 253.
- Roncarolo M. G, Bacchetta R, Bordignon C. et al. // Type 1 T regulatory cells. // Immunol. Rev, 2001, 182, 68−79.
- Rowley J.D. // Chromosome studies in the non-Hodgkin's lymphomas: the role of the 14- 18 translocation. //J. Clin. Oncol, 1988, 6, 919−925.
- Sakaguchi S. // Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. // Annu. Rev. Immunol, 2004, 22, 531−562.
- Sakaguchi S. // Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. // Nat. Immunol, 2005, 6, 345−352.
- Salomon B, Lenschow D. J, Rhee L. et al. // B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. // Immunity, 2000, 12, 431440.
- Sander C. A, Yano T, Clark H.M. et al. // p53 mutation is associated with progression in follicular lymphomas. // Blood, 1993, 82, 1994−2004.
- Sasada T, Kimura M, Yoshida Y. et al. // CD4+CD25+ regulatory T cells in /patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. // Cancer, 2003, 98, 1089−1099.
- Sato K.*, Yamashita N, Baba M. et al. // Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. // Blood, 2003, 101,3581−3589.
- Sato K, Yamashita N, Baba M. et al. // Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. // Immunity, 2003, 18,367−379.
- Schaefer C, Kim G. G, Albers A. et al. // Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. // Br. J. Cancer, 2005, 92, 913−920.
- Schubert L. A, Jeffery E, Zhang Y. et al. // Scurfm (FOXP3) acts as a repressor of transcription and regulates T cell activation. // J. Biol. Chem, 2001, 276, 37 672−37 679.
- Serra P, Amrani A, Yamanouchi J. et al. // CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. // Immunity, 2003, 19, 877−889.
- Sharma S, Yang S. C, Zhu L, et al. // Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. // Cancer Res, 2005, 65, 5211−5220.
- Shevach E. M, Thornton A, Suri-Payer E. // T lymphocyte- mediated control of autoimmunity. //Novartis Found Symp, 1998, 215, 200−211.
- Shimizu J, Yamazaki S, Sakaguchi S. // Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. //J. Immunol, 1999, 163, 5211−5218.
- Shimizu J, Yamazaki S, Takahashi T. et al. // Stimulation of CD25+CD4+ regulatory T cells through GITreg breaks immunological self-tolerance. // Nat. Immunol, 2002, 3, 135−142.
- ShindoM, YoshidaY. // Regulatory T cells and skin tumors. // Recent Pat. Inflamm. Allergy Drug. Discov, 2010, 4, 249−254.
- Solal-Celigny P, Roy P, Colombat P. et al. //2004. Follicular lymphoma international prognostic index. // Blood, 2004, 104, 1258−1265.
- Steinman R. M, Hawiger D, Nussenzweig M.C. // Tolerogenic dendritic cells. // Annu. Rev. Immunol, 2003, 21, 685−711.
- Suri-Payer E., Cantor H. // Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4+CD25+ T cells. // J. Autoimmun., 2001, 16, 115−123.
- Swerdlow S.H. // Pediatric follicular lymphomas, marginal zone lymphomas, and marginal zone hyperplasia. // Am. J. Clin. Pathol., 2004, 122 Suppl, S98−109.
- Takahashi T., Tagami T., Yamazaki S. et al. // Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. // J. Exp. Med., 2000, 192, 303 310.
- Tanaka H., Tanaka J., Kjaergaard J. et al. // Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. // J. Immunother., 2002, 25, 207−217.
- Thompson R.H., Kuntz S.M., Leibovich B.C. et al. // Tumor B7-H7 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. // Cancer Res., 2006, 66, 3381−5.
- Thornton A.M., Donovan E. E, Piccirillo C.A. et al. // Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. // J. Immunol, 2004, 172, 6519−6523.
- Thornton A.M., Piccirillo C. A, Shevach E.M. // Activation requirements for the induction of CD4+CD25+ T cell suppressor function. // Eur. J. Immunol, 2004, 34, 366−376.
- Thornton A.M., Shevach E.M. // CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. //J. Exp. Med, 1998, 188, 287−296.
- Tien A. H, Xu L, Helgason C.D. // Altered immunity accompanies disease progression in a mouse model of prostate dysplasia. // Cancer Res, 2005, 65, 2947−2955.
- Tilly H, Rossi A, Stamatoullas A. et al. // Prognostic value of chromosomal adnormalities in follicular lymphoma. // Blood, 1994, 84, 1043−1049.
- Tommasini A, Ferrari S, Moratto D. et al. // X-chromosome inactivation analysis in a female carrier of FOXP3 mutation. // Clin. Exp. Immunol, 2002, 130, 127−130.
- Torlakovic E. E, Aamot H. V, Heim S. // A marginal zone phenotype in follicular lymphoma with t (14−18) is associated with secondary cytogenetic aberrations typical of marginal zone lymphoma. // J. Pathol, 2006, 209, 258−264.
- Trzonkowski P, Szmit E, Mysliwska J. et al. // CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. // Clin. Immunol, 2004, 112, 258−267.
- Turk M. J, Guevara-Patino J. A, Rizzuto G.A. et al. // Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. // J. Exp. Med, 2004, 200, 771−782.
- Vaandragr J. W, Schuuring E, Raap T. et al. // Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpointflanking probes. // Genes Chromosomes Cancer, 2000, 27, 85−94.
- Valencia X, Stephens G, Goldbach-Mansky R. et al. // TNF downmodulates the function of human CD4+CD25hi Tregulatory cells. // Blood, 2006, 108, 253−61.
- Van Meirvenne S, Dullaers M, Heirman C. et al. // In vivo depletion of CD4+CD25+ regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNA-electroporated dendritic cells. // Mol. Ther, 2005, 12, 922−932.
- Verhasselt V, Vosters O, Beuneu C. et al. // Induction of FOXP3-expressing regulatory CD4pos T cells by human mature autologous dendritic cells. // Eur. J. Immunol, 2004, 34, 762−772.
- Vigouroux S, Yvon E, Biagi E. et al. // Antigen-induced regulatory T cells. // Blood, 2004, 104, 26−33.
- Viguier M, Lemaitre F, Verola O. et al. // Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. // J. Immunol. 2004, 173, 1444−1453.
- Virchow R. // Aetiologie der neoplastischen Geschwulste/Pathogenie der neoplastischen Geschwulste. // In: Hirschwald VvA, ed. Die Krankhaften Geschwustle. Berlin, Germany, 1863, 57−101.
- Virchow R. // Reizung und Reizbarkeit. // Arch. Pathol. Anat. Klin. Med, 1858, 14,1−63.
- Voorhees P.M., Carder K. A, Smith S.V. et al. // Follicular lymphoma with a burkitt translocation predictor of an aggressive clinical course: a case report and review of the literature. // Arch. Pathol. Lab. Med, 2004, 128, 210−213.
- Wahlin B.E., Sander B., Christensson B. et al. // CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. // Clin. Cancer Res., 2007, 13, 388−397.
- Walker M.R., Kasprowicz D.J., Gersuk V.H. et al. // 2003. Induction of Foxp3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. // J. Clin. Invest., 2003, 112: 1437−1443.
- Wang H.Y., Lee D.A., Peng G. et al. // Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. // Immunity, 2004, 20, 107−118.
- Wang S.A., Wang L., Hochberg E.P. et al. // Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. // Am. J. Surg. Pathol., 2005, 29, 1490−1496.
- Wang X., Zheng J., Liu J. et al. // Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. // Eur. J. Haematol., 2005, 75, 468−476.
- Wei W.Z., Jacob J.B., Zielinski J.F. et al. // Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. // Cancer Res., 2005, 65, 8471−8478.
- Wei W.Z., Morris G.P., Kong Y.C. // Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. // Cancer Immunol. Immunother., 2004, 53, 73−78.
- Weiner H.L. // Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. // Immunol. Rev., 2001, 182, 207−214.
- Weisenburger D.D., Anderson J., Armitage J. et al. // Grading of follicular lymphoma: diagnostic accuracy, reproducibility, and clinical relevance. // Mod. Pathol, 1998, 11, 142a.
- Wolf D, Rumpold H, Koppelstatter C. et al. // Telomere length of in vivo expanded CD4(+)CD25(+) regulatory T-cells is preserved in cancer patients. // Cancer Immunol. Immunother, 2005, 1−11.
- Workman C. J, Vignali D.A. // The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. // Eur. J. Immunol, 2003, 33, 970 979.
- Wu C, Zhu Y, Jiang J. et al. // Immunohistochemical localization of programmed death-1 ligand-1 (PD1-L1) in gastric carcinoma and its clinical significance. //Acta Histochem, 2006, 108, 19−24.
- Yagi H, Nomura T, Nakamura K. et al. // Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int. Immunol, 2004, 16, 11, 1643−1656.
- Yamamoto R, Nishikori M, Kitawaki T. et al. // PD-l-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. // Blood, 2008, 111,3220−4.
- Yamazaki S, IyodaT, Tarbell K. etal. // Direct expansion of functional CD25+CD4+ regulatory T cells by antigen-processing dendritic cells. // J. Exp. Med, 2003, 198, 235−247.
- Yang Z.Z.*, Novak A. J, Ziesmer S.C. et al. // Attenuation of CD8+ T-cell function by CD4+CD25+ regulatory T cells in B-cell non-Hodgkin's lymphoma. // Cancer Res, 2006, 66, 20, 10 145−10 152.
- Yang Z. Z, Novak A. J, Stenson M.J. et al. // Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. // Blood, 2006, 107, 3639−46.
- Yang Z. Z, Novak A. J, Ziesmer S.C. et al. // Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. // Cancer Res, 2009, 69, 5522−5530.
- Yang Z.Z., Novak A.J., Ziesmer S.C. et al. // CD70+ non-Hodgkin lymphoma H cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells. // Blood, 2007, 110, 2537−2544.
- Yu P., Lee Y., Liu W. et al. // Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. // J. Exp. Med., 2005, 201, 779−791.
- Zelenetz A.D., Campbell M.J., BahlerD.W. et al. // Follicular lymphoma: a model of lymphoid tumor progression in man. // Ann. Oncol., 1991, 2 (Suppl. 2), 115−122.
- Zelenetz A.D., Chen T.T., Levy R. // Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection. // J. Exp. Med., 1992, 176, 1137−1148.
- Zhang H., Chua K.S., Guimond M. et al. // Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. // Nat. Med., 2005, 11, 1238−1243.
- Zhao D.M., Thornton A.M., DiPaolo R.J. et al. // Activated CD4+CD25+ T cells selectively kill B lymphocytes. // Blood, 2006, 107, 3925−32.
- Zukerberg L.R., Medeiros L.J., Ferry J.A. et al. // Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features. // Am. J. Clin. Pathol., 1993, 100,373.385.